Expert consensus on off-label drug use in the three Northeastern provinces of China （solid tumors and hematology）

JIN Yao; TONG Zhiqiang; DONG Mei; CAI Shuang

doi:10.6039/j.issn.1001-0408.2023.23.01

您当前的位置：

首页 >

文章列表页 >

Expert consensus on off-label drug use in the three Northeastern provinces of China （solid tumors and hematology）

更新时间：2023-12-08

- Expert consensus on off-label drug use in the three Northeastern provinces of China （solid tumors and hematology）
- ZHONGGUO YAOFANG Vol. 34, Issue 23, Pages: 2817-2824(2023)
- 作者机构：
  
  1.哈尔滨医科大学附属肿瘤医院药学部，哈尔滨　150086
  2.中国医科大学附属第一医院药学部，沈阳　110001
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.23.01
  CLC： R95
- Published：15 December 2023，
  
  Received：17 July 2023，
  
  Revised：14 October 2023，
扫描看全文
金瑶,佟志强,董梅等.东北三省超说明书用药专家共识（实体瘤、血液病篇）[J].中国药房,2023,34(23):2817-2824.

JIN Yao,TONG Zhiqiang,DONG Mei,et al.Expert consensus on off-label drug use in the three Northeastern provinces of China （solid tumors and hematology）[J].ZHONGGUO YAOFANG,2023,34(23):2817-2824.
金瑶,佟志强,董梅等.东北三省超说明书用药专家共识（实体瘤、血液病篇）[J].中国药房,2023,34(23):2817-2824. DOI： 10.6039/j.issn.1001-0408.2023.23.01.

JIN Yao,TONG Zhiqiang,DONG Mei,et al.Expert consensus on off-label drug use in the three Northeastern provinces of China （solid tumors and hematology）[J].ZHONGGUO YAOFANG,2023,34(23):2817-2824. DOI： 10.6039/j.issn.1001-0408.2023.23.01.

摘要

目的

为医疗机构的合理用药提供理论依据，助力药事服务质量的提高，进而满足临床用药需求。

方法

采用共识会议法，由辽宁省药学会、吉林省药学会和黑龙江省药学会联合组织本区域内临床和药学专家，通过对东北三省医疗机构超说明书用药相关信息进行收集和整理，并考察、引用部分专家共识及用药目录中的超说明书用药信息，通过多次投票和探讨研究后形成共识。

结果

最终编写的《东北三省超说明书用药专家共识》中实体瘤、血液病篇总计收录了70种药品的198条超说明书用药信息。

结论

《东北三省超说明书用药专家共识》（实体瘤、血液病篇）为医疗机构治疗实体瘤和血液病提供了合理用药的理论依据，对提高药品治疗的有效性和安全性具有积极意义。

Abstract

OBJECTIVE

To provide theoretical basis for the rational use of drugs in medical institutions， assist in improving the quality of pharmaceutical services， and thus meet clinical drug demands.

METHODS

Adopting consensus meetings， Liaoning Pharmaceutical Association，Jilin Pharmaceutical Association and Heilongjiang Pharmaceutical Association collaborated with clinical and pharmaceutical experts in the region to compile the expert consensus on off-label drug use in the three Northeastern provinces of China after many votes and discussions by collecting and collating the information related to off-label drug use in medical institutions from the three northeastern provinces of China，and referring to and citing off-label drug use stated in some expert consensus and medication catalog.

RESULTS

Finally， a total of 198 pieces of off-label drug use information for 70 drugs were included in the two sections of solid tumors and hematological diseases in

Consensus of Experts on Drug Use beyond the Instructions in the Three Provinces of Northeast China

CONCLUSIONS

Consensus of Experts on Off-label Drug Use in the Three Northeastern Provinces of Northeast China

（solid tumors and hematology）offers a theoretical foundation for rational drug use in the treatment of solid tumors and hematological diseases within medical institutions，and has a positive significance in improving the effectiveness and safety of drug treatment.

关键词

超说明书用药实体瘤血液病东北三省合理用药专家共识

Keywords

solid tumorshematologythree Northeastern provinces of Chinarational drug useexpert consensus

references

钱素云，杨梅. 超说明书用药的现状及原则[J]. 中国小儿急救医学，2018，25（1）：1-3.

QIAN S Y，YANG M. Current situation and principles of off-label drug uses[J]. Chin Pediatr Emerg Med，2018，25（1）：1-3.

唐晓霞，白崧力，李珂佳. 某医院血液科24种抗肿瘤药超说明书用药评价[J]. 安徽医药，2023，27（3）：625-629.

TANG X X，BAI S L，LI K J. Evaluation of off-label use of 24 kinds of anti-tumor drugs in the department of hematology in a hospital[J]. Anhui Med Pharm J，2023，27（3）：625-629.

韩芙蓉，张弨，李彤，等. 基于循证药学的血液科药品说明书外用药情况分析与评价[J]. 临床药物治疗杂志，2023，21（7）：60-64.

HAN F R，ZHANG C，LI T，et al. Analysis and evaluation of off-label uses of hematological drugs based on evidence- based pharmacy[J]. Clin Med J，2023，21（7）：60-64.

张镭，谭玲，陆进. 超说明书用药专家共识[J]. 药物不良反应杂志，2015，17（2）：101-103.

ZHANG L，TAN L，LU J. Expert consensus on out-of-specification drug use[J]. Adverse Drug React J，2015，17（2）：101-103.

WEI G X，WU M，ZHU H，et al. Off-label use of antineoplastic drugs to treat malignancies：evidence from China based on a nationwide medical insurance data analysis[J]. Front Pharmacol，2021，12：616453.

雷玮成，杜宝萍，林晓泉，等. 2 198条儿童肿瘤科医嘱超说明书用药分析[J]. 中国医院用药评价与分析，2019，19（5）：612-615.

LEI W C，DU B P，LIN X Q，et al. Analysis on 2 198 medical orders with off-label medication in department of pediatric oncology[J]. Eval Anal Drug Use Hosp China，2019，19（5）：612-615.

孟新源，梁永红，阿提合尼木·艾买提，等. 2 000张门诊抗肿瘤药处方超药品说明书用药情况分析[J]. 中国医院用药评价与分析，2022，22（6）：758-760，764.

MENG X Y，LIANG Y H，Atihenimu·Aimaiti，et al. Analysis of off-label use of 2 000 outpatient anti-tumor drug prescriptions[J]. Eval Anal Drug Use Hosp China，2022，22（6）：758-760，764.

郝帅. 医院抗肿瘤药物超说明书使用调查分析[J]. 名医，2022（8）：45-47.

HAO S. Investigation and analysis on the use of anti-tumor drugs beyond the instructions in hospitals[J]. Renowned Dr，2022（8）：45-47.

杨春松，杨亚亚，林芸竹，等. 四川地区抗肿瘤药物风险分级现状及需求研究[J]. 儿科药学杂志，2023，29（2）：7-12.

YANG C S，YANG Y Y，LIN Y Z，et al. Study on the current status and demand of risk classification of antineoplastic drugs in Sichuan[J]. J Pediatr Pharm，2023，29（2）：7-12.

广东省药学会，中山大学孙逸仙纪念医院. 超药品说明书用药目录：2022年版新增用法[J]. 今日药学，2022，32（6）：401-408.

Guangdong Pharmaceutical Association，Sun Yai-Sen Memorial Hospital，Sun-Sen University.List of drugs beyond the drug instructions ：new usage in 2022 edition[J]. Pharm Today，2022，32（6）：401-408.

山东省药学会循证药学专业委员会. 山东省超药品说明书用药专家共识：2021年版[J]. 临床药物治疗杂志，2021，19（6）：9-40.

Evidence-based Pharmacy Committee of Shandong Pharmaceutical Expert consensus on off-label drug use of Shandong province：2021[J]. Clin Med J，2021，19（6）：9-40.

BRIERLEY J，O’SULLIVAN B，ASAMURA H，et al. Global Consultation on Cancer Staging：promoting consistent understanding and use[J]. Nat Rev Clin Oncol，2019，16（12）：763-771.

NCCN. Clinical practice guidelines in oncology-ovarian cancer including fallopian tube cancer and primary peritoneal cancer：2022 version 2[EB/OL].（2022-07-13）[2022-08-19]. http：//www.nccn.orghttp://www.nccn.org.

NCCN. Clinical practice guidelines in oncology-breast cancer：2022 version 4[EB/OL].（2022-06-21）[2022-08-19]. http：//www.nccn.orghttp://www.nccn.org.

中国肿瘤临床协会指南工作委员会.中国肿瘤临床协会（CSCO）乳腺癌诊疗指南[M]. 北京：人民卫生出版社，2022：1-197.

Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology （CSCO） breast cancer[M]. Beijing：People’s Medical Publishing House，2022：1-197.

中国肿瘤临床协会指南工作委员会. 中国肿瘤临床协会（CSCO）结直肠癌诊疗指南[M]. 北京：人民卫生出版社，2022：1-141.

Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology （CSCO） colorectal cancer[M]. Beijing：People’s Medical Publishing House，2022：1-141.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Consensus of Chinese experts on individualized medication management of imatinib for gastrointestinal stromal tumors

Expert consensus on prescription review rules of anticoagulants

CHINA PH ARMACY Volume 33，Number 15，August 15，2022 Semimonthly Table of Contents Expert consensus on the comprehensive clinical evaluation of lipid-lowering drugs under the centralized drug volume-based procurement policy in Shandong Province

CHINA PH ARMACY Volume 33，Number 9，May 15，2022 Semimonthly Table of Contents Hangzhou expert consensus on comprehensive clinical evaluation of drugs for chronic cardiovascular diseases

Related Author

Precision Pharmacy Working Committee of the Chinese Pharmacists Association

the Oncology Specialist Pharmacist Branch of the Chinese Pharmacists Association

the Writing Group of the Consensus of Chinese Experts on Individualized Medication Management of Imatinib for Gastrointestinal Stromal Tumors

Pharmaceutical Administration Committee of Chongqing Hospital Association

Qian Yan

Pharmacoeconomics Committee of Shandong Hospital Association

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰